Finance

Lists
1ZTS:BIT
Zoetis Inc
€61,60
-0,93%
(-0,58) 1D
2 Okt., 17:26:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1ZTS...
Open
€61,60
High
€61,60
Low
€61,60
Mkt. cap
30,91 mjd
Avg. vol.
384,00
Volume
8,00
52-wk high
€130,06
52-wk low
€61,04
No. of employees
14 k
Open
€61,60
High
€61,60
Low
€61,60
Mkt. cap
30,91 mjd
Avg. vol.
384,00
Volume
8,00
52-wk high
€130,06
52-wk low
€61,04
No. of employees
14 k
News stories
From web sources and news partners
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees14,5 k
Founded1952
HeadquartersParsippany-Troy Hills, New Jersey, Verenigde State van Amerika
SectorPharmaceutical industry
Websitezoetis.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
2,40 mjd
2,39 mjd
2,26 mjd
2,47 mjd
Cost of goods sold
682,00 m
711,00 m
640,00 m
670,00 m
Cost of revenue
682,00 m
711,00 m
640,00 m
670,00 m
Research and development expenses
170,00 m
199,00 m
180,00 m
173,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
572,00 m
618,00 m
584,00 m
589,00 m
Operating expense
774,00 m
848,00 m
795,00 m
793,00 m
Total operating expenses
1,46 mjd
1,56 mjd
1,44 mjd
1,46 mjd
Operating income
944,00 m
828,00 m
827,00 m
1,00 mjd
Other non operating income
-
-6,00 m
-1,00 m
-2,00 m
EBT including unusual items
887,00 m
761,00 m
758,00 m
866,00 m
EBT excluding unusual items
899,00 m
780,00 m
779,00 m
948,00 m
Income tax expense
166,00 m
158,00 m
157,00 m
175,00 m
Effective tax rate
18,71%
20,76%
20,71%
20,21%
Other operating expenses
-
-
-
-
Net income
721,00 m
603,00 m
601,00 m
691,00 m
Net profit margin
30,04%
25,26%
26,57%
28,00%
Earnings per share
1,70
1,48
1,53
1,87
Interest and investment income
26,00 m
25,00 m
21,00 m
16,00 m
Interest expense
-58,00 m
-57,00 m
-62,00 m
-61,00 m
Net interest expenses
-32,00 m
-32,00 m
-41,00 m
-45,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,07 mjd
903,00 m
946,00 m
1,12 mjd
Gain or loss from assets sale
-
-
-6,00 m
-1,00 m
AI content may include mistakes. Learn more
Google-programme